Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

denk pharma gmbh & co. kg - metformin (metformin hydrochloride) - tablets film-coated - 1000mg

Australia - English - Department of Health (Therapeutic Goods Administration)

boston scientific pty ltd -

United States - English - NLM (National Library of Medicine)

united therapeutics corporation - treprostinil (unii: rum6k67esg) (treprostinil - unii:rum6k67esg) - treprostinil 20 mg in 20 ml - remodulin is indicated for the treatment of pulmonary arterial hypertension (pah; who group 1) to diminish symptoms associated with exercise. studies establishing effectiveness included patients with nyha functional class ii-iv symptoms and etiologies of idiopathic or heritable pah (58%), pah associated with congenital systemic-to-pulmonary shunts (23%), or pah associated with connective tissue diseases (19%) [see clinical studies (14.1)] . in patients with pah requiring transition from epoprostenol, remodulin is indicated to diminish the rate of clinical deterioration. consider the risks and benefits of each drug prior to transition. none risk summary limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. however, there are risks to the mother and the fetus associated with pulmonary arterial hypertension (see clinical considerations) . in animal studies, no adverse reproductive and developmental effects were seen in rats

United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - treprostinil (unii: rum6k67esg) (treprostinil - unii:rum6k67esg) - treprostinil injection is indicated for the treatment of pulmonary arterial hypertension (pah; who group 1) to diminish symptoms associated with exercise. studies establishing effectiveness included patients with nyha functional class ii-iv symptoms and etiologies of idiopathic or heritable pah (58%), pah associated with congenital systemic-to-pulmonary shunts (23%), or pah associated with connective tissue diseases (19%) [see clinical studies (14.1)] . in patients with pah requiring transition from epoprostenol, treprostinil injection is indicated to diminish the rate of clinical deterioration. consider the risks and benefits of each drug prior to transition. none risk summary limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. however, there are risks to the mother and the fetus associated with pulmonary arterial hypertension (see clinical considerations) . in animal studies, no adverse reproductive and developmental

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - treprostinil (unii: rum6k67esg) (treprostinil - unii:rum6k67esg) - treprostinil is indicated for the treatment of pulmonary arterial hypertension (pah; who group 1) to diminish symptoms associated with exercise. studies establishing effectiveness included patients with nyha functional class ii-iv symptoms and etiologies of idiopathic or heritable pah (58%), pah associated with congenital systemic-to -pulmonary shunts (23%), or pah associated with connective tissue diseases (19%) [see clinical studies (14.1) ]. in patients with pah requiring transition from epoprostenol, treprostinil is indicated to diminish the rate of clinical deterioration. consider the risks and benefits of each drug prior to transition. none risk summary limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. however, there are risks to the mother and the fetus associated with pulmonary arterial hypertension (see clinical considerations) . in animal studies, no adverse reproductive and developmental effects were seen

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

denk pharma gmbh & co. kg - enalapril (enalapril maleate) - tablets - 10mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

denk pharma gmbh & co. kg - enalapril (enalapril maleate) - tablets - 20mg

United States - English - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - treprostinil (unii: rum6k67esg) (treprostinil - unii:rum6k67esg) - treprostinil injection is indicated for the treatment of pulmonary arterial hypertension (pah; who group 1) to diminish symptoms associated with exercise. studies establishing effectiveness included patients with nyha functional class ii-iv symptoms and etiologies of idiopathic or heritable pah (58%), pah associated with congenital systemic-to-pulmonary shunts (23%), or pah associated with connective tissue diseases (19%) [see clinical studies (14.1)]. in patients with pah requiring transition from epoprostenol, treprostinil injection is indicated to diminish the rate of clinical deterioration. consider the risks and benefits of each drug prior to transition. none risk summary limited case reports of treprostinil use in pregnant women are insufficient to inform a drug- associated risk of adverse developmental outcomes. however, there are risks to the mother and the fetus associated with pulmonary arterial hypertension (see clinical considerations ). in animal studies, no adverse reproductive and developmen

United States - English - NLM (National Library of Medicine)

dr.reddy's laboratories inc., - treprostinil (unii: rum6k67esg) (treprostinil - unii:rum6k67esg) - treprostinil injection is indicated for the treatment of pulmonary arterial hypertension (pah; who group 1) to diminish symptoms associated with exercise. studies establishing effectiveness included patients with nyha functional class ii-iv symptoms and etiologies of idiopathic or heritable pah (58%), pah associated with congenital systemic-to-pulmonary shunts (23%), or pah associated with connective tissue diseases (19%) [see clinical studies (14.1)] . in patients with pah requiring transition from epoprostenol, treprostinil injection is indicated to diminish the rate of clinical deterioration. consider the risks and benefits of each drug prior to transition. none risk summary limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. however, there are risks to the mother and the fetus associated with pulmonary arterial hypertension (see clinical considerations) . in animal studies, no adverse reproductive and developmental

Canada - English - Health Canada

bayer inc - iopromide - solution - 50% - iopromide 50% - roentgenography